Rafael Holdings, Inc. Class B (RFL) News
Filter RFL News Items
RFL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RFL News Highlights
- RFL's 30 day story count now stands at 3.
- Over the past 29 days, the trend for RFL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about RFL are AMP, LI and UL.
Latest RFL News From Around the Web
Below are the latest news stories about RAFAEL HOLDINGS INC that investors may wish to consider to help them evaluate RFL as an investment opportunity.
Rafael Holdings GAAP EPS of -$0.15, revenue of $68KMore on Rafael Holdings... |
Rafael Holdings Reports First Quarter Fiscal 2024 Financial ResultsCompany remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investmentsNEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023. “During fiscal 2024, we will continue to focus on advancing our existing portfolio and identifying strategic investments in companies which have the pot |
Cyclo Therapeutics Reports Third Quarter 2023 Financial ResultsGAINESVILLE, Fla., November 15, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023. |
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial ResultsCompany positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunitiesNEWARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the fourth quarter and full year of fiscal 2023 - the three and twelve months ended July 31, 2023. “During fiscal 2023, we made meaningful progress toward expanding our portfolio through strategic investments in companies which have th |
Cyclo Therapeutics Reports Second Quarter 2023 Financial ResultsGAINESVILLE, Fla., August 15, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2023. |
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.GAINESVILLE, Fla., August 02, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed the previously announced private placement with Rafael Holdings, Inc. (NYSE:RFL) ("Rafael") for the purchase of 4,000,000 shares of common stock of Cyclo Therapeutics and warrants to |
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business UpdateSince the end of the third quarter, we made an initial $2.1 million investment in Cyclo Therapeutics, Inc. (Nasdaq: CYTH) and have an agreement to increase our investment by $5 millionNEWARK, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter of fiscal 2023 for the three months ended April 30, 2023, as well as the nine months ended April 30, 2023. “We continue to seek to expand our portfolio through strategic inves |
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private PlacementGAINESVILLE, Fla., June 05, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has entered into a binding agreement with Rafael Holdings, Inc. (NYSE:RFL) ("Rafael") under which Rafael has agreed to purchase 4,000,000 shares of common stock of Cyclo Therapeutics and warrants |
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial ResultsGAINESVILLE, Fla., May 15, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the first quarter of 2023 and provided a business update. |
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)GAINESVILLE, Fla., May 02, 2023--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed a private placement of its securities with Rafael Holdings, Inc. (NYSE:RFL) ("Rafael") for the purchase of 2,514,970 shares of common stock and warrants to purchase an additional 2,514, |